Bavarian Nordic – Completion of Share Buy-Back Program
01 February 2025 - 6:31AM
UK Regulatory
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, January 31,
2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the
share buy-back program, which was announced and initiated on
January 9, 2025, has now been completed, reaching an aggregate
amount of approximately DKK 150 million as planned. Bavarian Nordic
will hold the shares bought back as treasury stock, for the purpose
of adjusting the capital structure and meeting the long-term
obligations relating to the Company’s share-based incentive
programs for the Board of Directors and Executive Management, in
accordance with the Company’s remuneration policy.
The program was executed in accordance with
Regulation (EU) No. 596/2014 (as amended) of the European
Parliament and of the Council on market abuse and Commission
Delegated Regulation (EU) 2016/1052, which together constitute the
Safe Harbour Regulation.
A total of 760,275 shares were repurchased under
the program. Since the last announcement of transactions under the
program on January 27, 2025, the following transactions have been
made:
|
|
Number of shares |
Average purchase price, DKK |
Transaction value, DKK |
|
Accumulated until January 27 |
588,000 |
197.87 |
116,344,980 |
|
January 27, 2025 |
60,000 |
192.51 |
11,550,600 |
|
January 28, 2025 |
42,000 |
194.97 |
8,188,740 |
|
January 29, 2025 |
40,000 |
197.15 |
7,886,000 |
|
January 30, 2025 |
19,000 |
197.99 |
3,761,810 |
|
January 31, 2025 |
11,275 |
201.09 |
2,267,290 |
|
Accumulated under the program |
760,275 |
197.30 |
149,999,420 |
The details for each transaction made under the
share repurchase program are published on bavarian-nordic.com.
Following these transactions, Bavarian Nordic
holds a total of 1,044,510 treasury shares, corresponding to 1.32%
of the Company’s share capital.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to
improve health and save lives through innovative vaccines. We are a
preferred supplier of mpox and smallpox vaccines to governments to
enhance public health preparedness and have a leading portfolio of
travel vaccines. For more information, visit
www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
Contact investors:
Europe: Rolf Sass Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors,
graham@paddockcircle.com, Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications,
nise@bavarian-nordic.com, Tel: + 45 53 88 06 03
Company Announcement no. 05 / 2025
- 2025-05-en
- 2023-05-appendix-en
Bavarian Nordic AS (TG:BV3)
Historical Stock Chart
From Jan 2025 to Feb 2025
Bavarian Nordic AS (TG:BV3)
Historical Stock Chart
From Feb 2024 to Feb 2025
